New immune combo shows promise in early breast cancer trial
NCT ID NCT04895761
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new immune-boosting drug (DPX-Survivac) combined with hormone therapy, with or without low-dose radiation or chemotherapy, in women with hormone receptor-positive, HER2-negative breast cancer. The main goal is to check safety before standard surgery. About 18 participants will be enrolled across three treatment groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?